The global generic injectables market reached a value of more than US$ 43 Billion in 2016, exhibiting a CAGR of around 9% during 2009-2016.
Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Moreover, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.
Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market. According to
The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.
The report has also analysed the competitive landscape of the market with some of the key players being Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter.
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4 Introduction 4.1 Overview 4.2 Key Industry Trends
5 Global Generic Drug Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Region 5.4 Market Forecast 5.5 Major Players
6 Global Generic Drug Delivery Market 6.1 Oral 6.2 Injectables 6.3 Dermal/Topical 6.4 Inhalers
7 Global Generic Injectables Market 7.1 Market Overview 7.2 Market Performance 7.3 Market Breakup by Region 7.4 Market Breakup by Therapeutic Area 7.5 Market Breakup by Distribution Channel 7.6 Market Forecast
8 Global Generic Injectables Market: Performance of Key Regions
9 Market by Therapeutic Area 9.1 Oncology 9.2 Anaesthesia 9.3 Anti-infectives 9.4 Parenteral Nutrition 9.5 Cardiovascular
10 Market by Distribution Channel 10.1 Hospitals 10.2 Retail Pharmacy Stores
11 Global Generic Injectable Market: Competitive Landscape 11.1 Competitive Structure 11.2 Market Breakup by Key Players
12 Generic Injectable Manufacturing Process 12.1 Product Overview 12.2 Detailed Process Flow (Injectable) 12.3 Various Types of Unit Operations Involved 12.4 Mass Balance and Raw Material Requirements
13 Project Details, Requirements and Costs Involved 13.1 Land Requirements and Expenditures 13.2 Construction Requirements and Expenditures 13.3 Plant Machinery 13.4 Machinery Pictures 13.5 Raw Material Requirements and Expenditures 13.6 Packaging Requirements and Expenditures 13.7 Transportation Requirements and Expenditures 13.8 Utility Requirements and Expenditures 13.9 Manpower Requirements and Expenditures 13.10 Other Capital Investments
14 Loans and Financial Assistance
15 Project Economics 15.1 Capital Cost of the Project 15.2 Techno-Economic Parameters 15.3 Product Pricing and Margins Across Various Levels of the Supply Chain 15.4 Taxation and Depreciation 15.5 Income Projections 15.6 Expenditure Projections 15.7 Financial Analysis 15.8 Profit Analysis